TelyRx broadens its women's health portfolio by partnering with SISTERLY to offer new menopause supplements alongside its established prescription-based treatment options.
TelyRx Holdings Inc. is expanding its women's health portfolio by partnering with SISTERLY to offer menopause supplements alongside its existing prescription treatments. This strategic move allows the company to capture a broader market segment by providing non-prescription options for women navigating perimenopause and menopause, diversifying its revenue streams beyond traditional pharmaceuticals.
The partnership aims to broaden the options available for women navigating perimenopause and menopause by combining prescription treatments with new supplement offerings.
It represents an expansion of their women's health portfolio, moving from strictly prescription-based treatments to a more comprehensive approach that includes supplements.
TelyRx Holdings Inc. (TSX: TELY) has entered a strategic partnership with SISTERLY to integrate menopause supplements into its existing healthcare product line. This move aims to diversify the company's offerings beyond traditional prescription treatments for women navigating perimenopause and menopause.
The partnership aims to expand TelyRx's women's health portfolio by offering menopause supplements that complement its existing prescription treatments.